bronchitis/diarrhea

Morphological, microstereological and immunohistoenzymatic technique were used to assess jejunal biopsy samples obtained from 17 infants suffering from chronic diarrhoea and bronchitis spastica (the study group), and 5 infants with chronic diarrhoea and weight deficiency (group G). In the first

A nephropathogenic Massachusetts strain of infectious bronchitis virus, designated H13-IB virus, was isolated from the kidneys of broilers in a commercial flock. Respiratory distress, diarrhea, depression, and high mortality were present. Gross renal lesions consisted of pale coloration, mottling,

In this double-blind study, 319 patients (133 men, 186 women) with acute bronchitis were randomly assigned to receive 200 mg of loracarbef twice daily (n = 160; mean age, 42 years) or 250 mg of cefaclor thrice daily (n = 159; mean age, 43 years) for seven days. Clinical and bacteriologic responses

A nephropathogenic Massachusetts strain of infectious bronchitis virus (IBV) designated H13-IBV was isolated from the kidneys of commercial broilers. H13-IBV caused respiratory distress, depression, and diarrhea in specific-pathogen-free chickens. Gross renal lesions included pale coloration,

In two multicenter trials, lomefloxacin and cefaclor were compared as treatments for acute bacterial exacerbations of chronic bronchitis. In total, 522 adult outpatients were enrolled at 50 centers in the United States. Patients were randomized to treatment groups receiving either 400 mg

BACKGROUND Shorter than traditional 7- to 14-day treatment regimens have demonstrated efficacy in treatment of an acute exacerbation of chronic bronchitis (AECB). OBJECTIVE Perform a clinical efficacy study comparing 5 days of cefprozil therapy to 10 days of clarithromycin in treating an

In this study, a reverse transcription loop-mediated isothermal amplification (RT-LAMP) was developed for detection of porcine epidemic diarrhea virus (PEDV). Six primers were designed to amplify the nucleocapsid (N) gene of PEDV. The optimization, sensitivity, and specificity of the RT-LAMP were

BACKGROUND Although acute exacerbations of chronic bronchitis (AECBs) are common, there has been no metaanalysis that focused on the optimum regimen. METHODS To evaluate the comparative effectiveness and safety of first-line antimicrobial agents (ie, amoxicillin, ampicillin, pivampicillin,

OBJECTIVE The aim of this study was to compare the efficacy and safety of clarithromycin extended-release (ER) tablets and immediate-release (IR) tablets. METHODS This was a Phase III, open-label, randomized, multicenter, comparative study in ambulatory patients with a diagnosis of acute

Two controlled clinical trials compared loracarbef (LY163892 with amoxicillin/clavulanate or amoxicillin in the treatment of acute exacerbations of chronic bronchitis. Collectively, of 1,057 patients enrolled, 390 qualified for analysis: group 1 comprised 200 patients treated with loracarbef (400 mg

OBJECTIVE To compare the efficacy and safety of oral azithromycin 500 mg once daily for 3 days with those of oral clarithromycin 500 mg twice daily for 10 days. METHODS Randomized, double-blind, double-dummy, multicenter study. METHODS Seventy-six study centers in eight countries (Argentina, Brazil,

BACKGROUND Clarithromycin has an established efficacy and safety profile in the treatment of respiratory tract infections. OBJECTIVE The purpose of this study was to compare the clinical and bacteriologic efficacy and tolerability of clarithromycin extended-release and immediate-release formulations

In this randomized, open-label, dose-comparative study, 18 investigators enrolled 466 patients with acute bronchitis. Patients were randomly assigned to receive either 600 mg of cefdinir once daily (QD) or 300 mg of cefdinir twice daily (BID) for 10 days. Both microbiologic and clinical efficacy

Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5- or 10-day treatment with cefuroxime axetil with those of 10-day treatment with

In this single-blind study, 488 patients with acute bronchitis were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for seven days. Treatment efficacy was evaluated in 98 patients treated with loracarbef and in 99 treated with